Trending...
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
- Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
Single ~ CS Genetics, a leading company in next-generation single-cell genomics, has announced the launch of their latest product, the SimpleCell™ 3' Gene Expression kits. This is the company's first commercial offering and is designed to make single-cell transcriptomics more accessible and scalable.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
The SimpleCell™ platform utilizes Kinetic Confinement, a revolutionary molecular process, to provide an instrument-free and scalable solution for single-cell genomics. This technology has been in development for several years and is now being released commercially.
Luke Edelman, Founder and Chief Technology Officer at CS Genetics, expressed his excitement about the launch of SimpleCell™. He stated, "After several years of development, we are so excited to be releasing our first SimpleCell™ products commercially. Single cell is a very important and impactful modality for biological measurement, and we feel strongly that a diverse ecosystem of technology platforms – now including Kinetic Confinement and SimpleCell™ – is good for the field and for the cadence of discovery."
More on The PennZone
- Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
- Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
- Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
The SimpleCell™ 3' Gene Expression kits have several key features that make them stand out in the market. These include a single-day cells-to-sequencer workflow using standard lab equipment and pipetting, cost-effectiveness at under $500 per sample regardless of experiment scale or purchase volume, and compatibility with various sample types such as blood/PBMCs, cell lines, disaggregated solid tissues, and more.
CS Genetics will be showcasing details about Kinetic Confinement technology and the SimpleCell™ product line at the 2024 Annual Meeting of the American Society for Human Genetics in Denver. Attendees can visit CS Genetics at booth 402 or join the SimpleCell™ CoLab talk on Wednesday, November 6th at 4:00 PM in Theater 3 to learn more about the future of single-cell genomics.
Early customers of SimpleCell™ have already expressed their satisfaction with the product. Charlly Kao, Principal Scientist at the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, shared, "We've been eagerly waiting for something like SimpleCell™ that can perform single-cell transcriptome profiling in a flexible, instrument-free, and simple-to-use workflow at a more attractive price point."
More on The PennZone
- New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
- Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
- "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
- CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
- Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
Hákon Hákonarson, Director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine, also commented on the potential impact of SimpleCell™. He said, "Kinetic Confinement and the SimpleCell™ platform are timely new additions to the single cell universe. As a translational research facility with access to a very large number of clinical specimens, we are particularly excited about the opportunities presented by the platform to enable significantly larger-scale single cell studies than has been realistically possible with other tools."
Yuriy Alekseyev, director of the Single Cell and NGS core laboratory at Boston University Chobanian & Avedisian School of Medicine, also praised SimpleCell™ for its affordability and ease-of-use. He stated, "SimpleCell™ checks these boxes well. It's simple to set up, cost-effective, and a welcome addition for users who've been looking for a platform that doesn't require a huge learning curve or large costs for each experiment."
The SimpleCell™ 3' Gene Expression kits are available in 8-sample and 16-sample sizes and can now be ordered for shipment across the U.S., U.K., Europe, and select global regions through CS Genetics' website. To learn more about this innovative product or to place an order, visit www.csgenetics.com.
Filed Under: Business
0 Comments
Latest on The PennZone
- Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
- The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
- Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
- November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
- Valeo Health Leads a New Era of Longevity and Preventive Health in the UAE
- Torch Entertainment Presents The Frozen Zoo
- Philadelphia Based Teen Singer/Songwriter and his Producer Brother Release First Single
- Sweet Memories Vintage Tees Debuts Historic ORCA™ Beverage Nostalgic Soda Collection
- UK Financial Ltd Celebrates Global Recognition as MayaCat (MCAT) Evolves Into SMCAT — The World's First Meme Coin Under ERC-3643 Compliance
- U.S. Military to Benefit from Drone Tech Agreement with NovaSpark Energy, Plus Longer NASA Space Missions via Solar Power Leader: Ascent Solar $ASTI
- $76 Million in Gold & Silver Holdings and Expanding Production — Pioneering the Future of Gold: Asia Broadband Inc. (Stock Symbol: AABB) is Surging
- Wohler announces three SRT monitoring enhancements for its iVAM2-MPEG monitor and the addition of front panel PID selection of A/V/subtitle streams
- Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
- 20 Million Financing to Accelerate Growth and Advance Digital Asset Strategy Secured for Super League (N A S D A Q: SLE)
- uCAR Trading Launches goldsilbermarkt.de, a New Online Shop for Precious Metals
- Webinar Announcement: Reputational Risk Management in Internal Investigations: Controlling the Narrative Before, During, and After a Crisis
- Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
- Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes